194 related articles for article (PubMed ID: 35144647)
1. Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study.
Ogura Y; Terashima K; Nanno Y; Park S; Suga M; Takahashi D; Matsuo Y; Sulaiman NS; Tokumaru S; Okimoto T; Toyama H; Fukumoto T
Radiat Oncol; 2022 Feb; 17(1):32. PubMed ID: 35144647
[TBL] [Abstract][Full Text] [Related]
2. Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study.
Ami K; Terashima K; Ishida J; Suga M; Okawa T; Takahashi D; Park S; Matsuo Y; Nanno Y; Tokumaru S; Okimoto T; Toyama H; Fukumoto T
Radiat Oncol; 2023 Aug; 18(1):131. PubMed ID: 37553705
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis.
Terashima K; Demizu Y; Hashimoto N; Jin D; Mima M; Fujii O; Niwa Y; Takatori K; Kitajima N; Sirakawa S; Yonson K; Hishikawa Y; Abe M; Sasaki R; Sugimura K; Murakami M
Radiother Oncol; 2012 Apr; 103(1):25-31. PubMed ID: 22300608
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-based concurrent chemoradiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Wang BH; Cao WM; Yu J; Wang XL
Asian Pac J Cancer Prev; 2012; 13(5):2129-32. PubMed ID: 22901181
[TBL] [Abstract][Full Text] [Related]
5. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
Ogawa K; Ito Y; Hirokawa N; Shibuya K; Kokubo M; Ogo E; Shibuya H; Saito T; Onishi H; Karasawa K; Nemoto K; Nishimura Y;
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):559-65. PubMed ID: 22019243
[TBL] [Abstract][Full Text] [Related]
6. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.
Murphy JD; Adusumilli S; Griffith KA; Ray ME; Zalupski MM; Lawrence TS; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):801-8. PubMed ID: 17379445
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
8. "HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.
Datta NR; Pestalozzi B; Clavien PA; Siebenhüner A; Puric E; Khan S; Mamot C; Riesterer O; Knuchel J; Reiner CS; Bodis S;
Radiat Oncol; 2017 Nov; 12(1):183. PubMed ID: 29162142
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Huang WK; Kuo YC; Tsang NM; Hsu HC; Shen WC; Chou WC; Yang TS; Chen JS
Anticancer Res; 2014 Nov; 34(11):6755-61. PubMed ID: 25368287
[TBL] [Abstract][Full Text] [Related]
10. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.
Gemenetzis G; Groot VP; Blair AB; Laheru DA; Zheng L; Narang AK; Fishman EK; Hruban RH; Yu J; Burkhart RA; Cameron JL; Weiss MJ; Wolfgang CL; He J
Ann Surg; 2019 Aug; 270(2):340-347. PubMed ID: 29596120
[TBL] [Abstract][Full Text] [Related]
11. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
[TBL] [Abstract][Full Text] [Related]
12. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
Polistina F; Costantin G; Casamassima F; Francescon P; Guglielmi R; Panizzoni G; Febbraro A; Ambrosino G
Ann Surg Oncol; 2010 Aug; 17(8):2092-101. PubMed ID: 20224860
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
14. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Paik WH; Lee SH; Kim YT; Park JM; Song BJ; Ryu JK
J Korean Med Sci; 2015 Jul; 30(7):917-23. PubMed ID: 26130955
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Mayahara H; Ito Y; Morizane C; Ueno H; Okusaka T; Kondo S; Murakami N; Morota M; Sumi M; Itami J
BMC Cancer; 2012 Dec; 12():609. PubMed ID: 23256481
[TBL] [Abstract][Full Text] [Related]
16. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
Brade A; Brierley J; Oza A; Gallinger S; Cummings B; Maclean M; Pond GR; Hedley D; Wong S; Townsley C; Brezden-Masley C; Moore M
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1027-36. PubMed ID: 17197132
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
Hunter KU; Feng FY; Griffith KA; Francis IR; Lawrence TS; Desai S; Murphy JD; Zalupski MM; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):921-6. PubMed ID: 22208966
[TBL] [Abstract][Full Text] [Related]
18. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer.
Takatori K; Terashima K; Yoshida R; Horai A; Satake S; Ose T; Kitajima N; Kinoshita Y; Demizu Y; Fuwa N
J Gastroenterol; 2014 Jun; 49(6):1074-80. PubMed ID: 23846547
[TBL] [Abstract][Full Text] [Related]
19. Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
Huang J; Robertson JM; Ye H; Margolis J; Nadeau L; Yan D
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1120-5. PubMed ID: 22099048
[TBL] [Abstract][Full Text] [Related]
20. Concurrent chemoradiotherapy with gemcitabine plus regional hyperthermia for locally advanced pancreatic carcinoma: initial experience.
Ohguri T; Imada H; Yahara K; Narisada H; Morioka T; Nakano K; Korogi Y
Radiat Med; 2008 Dec; 26(10):587-96. PubMed ID: 19132489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
